Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03186430 · ClinicalTrials.gov registry record · NA

PreTeenVax Evaluation

A NA study of Human Papilloma Virus, sponsored by Emory University.

Completed
Registry status
NA
Development phase
168
Enrollment target
6
Study locations

NCT03186430: Completed NA study of Human Papilloma Virus, sponsored by Emory University.

NCT03186430 is a NA study of Human Papilloma Virus that has completed, run by Emory University. The registered enrollment target is 168 participants, below the 8,437-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03186430, a NA study of Human Papilloma Virus, has completed, sponsored by Emory University.

COMPLETED
Registry status
NA
Development phase
168 participants
Enrollment target
6
Study locations

Study Summary

The primary research aim of this project is to test the effectiveness of a comprehensive, evidence-based vaccine promotion toolkit implemented in the pediatric healthcare setting on increasing the likelihood that adolescents in Georgia will initiate and complete the Human Papillomavirus (HPV) vaccine series. Secondary research aims include assessing the impact of the comprehensive toolkit on 1) patient and parent knowledge and attitudes regarding HPV vaccine, and 2) provider recommendation of HPV vaccine for males and females in the recommended age range (11-12 years). The intervention toolkit will include evidence-based components aimed at the practice-level, provider-level and parent-level that will be tested through a cluster-randomized trial design. The primary hypothesis is that implementation of the comprehensive vaccine promotion toolkit in the pediatric health care setting will increase the likelihood that an adolescent receives initiates HPV vaccination. At the initial visit, parents of adolescent patients at participating pediatric practices will complete a brief questionnaire assessing their knowledge, attitudes, and beliefs about adolescent health, including protection against infectious diseases during adolescence. The parents will be contacted again three months later to complete a short follow-up interview on the general health of their adolescent child, immunization status, and attitudes regarding vaccination.

Primary Outcome

During the follow-up interview, parents are asked if their child received the HPV vaccine during the visit with their pediatrician when they enrolled in this study. Possible responses are: * Yes, they received a dose of this vaccine * No, the received a dose of this vaccine before that visit * No, but they received a dose of this vaccine at a later visit * No, they have not received this vaccine * Don't know

Conditions Studied

Interventions

  • BEHAVIORAL Comprehensive Vaccine Promotion Package

Study Locations (6)

Georgia

  • DV Pediatrics - Canton
  • Crescent Pediatrics - Duluth
  • Lawrenceville Pediatrics - Lawrenceville Office - Lawrenceville
  • West Atlanta Pediatrics - Lithia Springs
  • Lawrenceville Pediatrics - Loganville Office - Loganville
  • Northlake Pediatric Associates - Stone Mountain

Trial Details

FieldValue
Enrollment Target 168 participants
Start Date 2017-06-14
Est. Completion 2018-07-31
Phase NA
Emory University

1,208 total trials

What the finished NCT03186430 record still lists

NCT03186430 is an interventional study that assigns participants to a tested intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap, below the 8,437-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Human Papilloma Virus appearing as the primary indexed condition, and to 1 intervention - of which Comprehensive Vaccine Promotion Package is the first listed.

NCT03186430 lists 6 locations in 1 state (Georgia).

Frequently Asked Questions

What is clinical trial NCT03186430 about?

NCT03186430 is a clinical study titled "PreTeenVax Evaluation". The primary research aim of this project is to test the effectiveness of a comprehensive, evidence-based vaccine promotion toolkit implemented in the pediatric healthcare setting on increasing the likelihood that adolescents in Georgia will initiate and complete the Human Papillomavirus (HPV) vaccin...

What is the current status of trial NCT03186430?

This trial is currently completed. It is a NA study. The enrollment target is 168 participants. The study started on 2017-06-14. Estimated completion is 2018-07-31.

What conditions does trial NCT03186430 study?

This clinical trial studies the following conditions: Human Papilloma Virus.

What interventions are being tested in trial NCT03186430?

The interventions under investigation include: Comprehensive Vaccine Promotion Package (BEHAVIORAL).

Who is sponsoring clinical trial NCT03186430?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03186430 being conducted?

This trial has 6 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Human Papilloma Virus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03186430's enrollment target sits among peer trials

168 19th of 39 higher than 21 of 39 other Human Papilloma Virus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Human Papilloma Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02118922 · 168 participants

    A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

  • NCT03536897 · 168 participants

    IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry

  • NCT04078230 · 168 participants · NA

    Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

  • NCT04159168 · 168 participants · NA

    Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03186430, the US trial registry maintained by the National Library of Medicine. NCT03186430 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.